Merck’s Molnupiravir: When a Private-Public Partnership Bears Fruit

As Merck and regulators around the world race to get molnupiravir approved for the treatment of COVID-19  - a U.S. Food and Drug Administration expert panel will deliberate its fate on November 30 – it may be important to look at just how this potential “miracle drug” came to be.